PASylated interferon alpha - XL-protein GmbH

Drug Profile

PASylated interferon alpha - XL-protein GmbH

Alternative Names: PAS-IFNα; xl-080

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XL-protein GmbH
  • Class Anti-infectives; Anti-inflammatories; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Infections; Inflammation

Highest Development Phases

  • Preclinical Infections; Inflammation

Most Recent Events

  • 09 Aug 2016 PASylated interferon alpha - XL-protein GmbH is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/
  • 09 Aug 2016 Preclinical trials in Infections in Germany (unspecified route)
  • 09 Aug 2016 Preclinical trials in Inflammation in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top